AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Ultragenyx's Q2 earnings exceed expectations, price target lowered to $128 by Canaccord.
ByAinvest
Friday, Aug 8, 2025 6:33 pm ET1min read
Ultragenyx's Q2 25 earnings report exceeded expectations, with strong demand for commercial franchises. Canaccord analyst Whitney Ijem lowered the price target to $128 from $136 and maintains a Buy rating. The firm reaffirmed FY25 guidance and outlook for 2027 full year GAAP profitability.
Ultragenyx Pharmaceutical Inc. delivered a stronger-than-expected earnings report for the second quarter of 2025, with earnings per share (EPS) of -$1.17, surpassing the forecast of -$1.30. The company also reported revenue of $166 million, exceeding the anticipated $161.97 million. Following the announcement, Ultragenyx’s stock rose by 1.58% during regular trading hours and gained an additional 3.16% in the aftermarket, reaching $29.36 [1].Key Takeaways
Ultragenyx reported a narrower loss than expected, beating EPS forecasts by $0.13. Revenue for Q2 2025 reached $166 million, a 13% increase from the previous year. The company maintains strong guidance for 2025, projecting revenue growth between 14% and 20% [1].
Market Reaction
Following the earnings release, Ultragenyx’s stock experienced a positive uptick, rising 1.58% during regular trading hours and an additional 3.16% in the aftermarket. While this increase highlights investor confidence, the stock has faced challenges, with a year-to-date decline of 31.26%. Trading at a Price/Book ratio of 18.61, the stock commands a premium valuation despite current market headwinds [1].
Analysts' Views
Canaccord analyst Whitney Ijem lowered the price target to $128 from $136 and maintains a Buy rating, reaffirming the firm's FY25 guidance and outlook for 2027 full-year GAAP profitability [1].
Outlook & Guidance
Ultragenyx projects full-year 2025 revenue between $640 million and $670 million, indicating a growth rate of 14% to 20%. The company remains committed to achieving GAAP profitability by 2027, with a focus on strategic product launches and resolving regulatory challenges [1].
References
[1] https://www.investing.com/news/transcripts/earnings-call-transcript-ultragenyx-q2-2025-beats-eps-forecast-stock-rises-93CH-4171699
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet